We are developing a portfolio of potentially first-in-class and best-in-class compounds with the aim of improving patient outcomes and easing the burden that mental health conditions have on individuals, healthcare systems and society.
Our next-generation psychedelic-based treatments have been designed to be administered in a short clinic visit, be well-tolerated and deliver rapid, robust and lasting treatment effects.
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
